title: Possible recurrence of symptoms after discontinuation of omalizumab in anti-IgE-assisted desensitization to egg.
authors.affiliation: Unit of Pediatric Pulmonology and Allergy, Children's Hospital La Fe, Instituto de Investigacion Sanitaria La Fe, Valencia, Spain. ilafu@hotmail.com.
authors.forename: Isabel
authors.initials: I
authors.lastname: Lafuente
authors.forename: Angel
authors.initials: A
authors.lastname: Mazon
authors.forename: Maria
authors.initials: M
authors.lastname: Nieto
authors.forename: Sonia
authors.initials: S
authors.lastname: Uixera
authors.forename: Raquel
authors.initials: R
authors.lastname: Pina
authors.forename: Antonio
authors.initials: A
authors.lastname: Nieto
mesh_terms: D000485:Allergens / Q000276:immunology; D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D003888:Desensitization, Immunologic / Q000379:methods*; D021181:Egg Hypersensitivity / Q000276:immunology / Q000628:therapy*; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D007223:Infant; D000069444:Omalizumab; D010059:Ovomucin / Q000276:immunology; D010063:Ovum / Q000276:immunology; D012008:Recurrence; D016896:Treatment Outcome; D028761:Withholding Treatment
chemical_list: D000485:Allergens; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab; D010059:Ovomucin; D007073:Immunoglobulin E